Poor
Not Aligned
Patient Risk:
Medium
Summary
Only the general indication statements are supported by the provided label text (Indications and Usage). The majority of other claims (Mexico-specific availability/verification, pharmacy substitution practices, alternative GLP-1 selection, and resource for IP/brand landscape) are not supported by the supplied prescribing information and include operational guidance not present in the label.
Category Scores
Accurate Statements
Victoza (liraglutide) is a prescription medicine used to improve blood sugar control in adults with type 2 diabetes.
1 INDICATIONS AND USAGE: adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
Victoza (liraglutide) is used, in some patients, to reduce cardiovascular risk.
1 INDICATIONS AND USAGE: reduce the risk of major adverse cardiovascular events in adults with type 2 diabetes mellitus and established cardiovascular disease.
Unsupported Statements
Availability and brand labeling of medications can vary by country.
No provided label text addresses country-specific availability or labeling variability.
In Mexico, the key next step for confirming Victoza status is verifying the exact product status including brand name, dosage strengths, and whether it is sold via regular pharmacy channels or through specific wholesalers.
No provided label text provides Mexico-specific product verification steps or wholesale-channel guidance.
In Mexico, when looking for Victoza, a pharmacy can be asked to confirm the active ingredient is liraglutide.
While the label states VICTOZA contains liraglutide, it does not provide pharmacy verification instructions or Mexico-specific guidance.
In Mexico, when looking for Victoza, a pharmacy can be asked to confirm the brand name is Victoza (if requested).
No provided label text addresses pharmacy brand-name confirmation practices.
In Mexico, when looking for Victoza, a pharmacy can be asked to confirm dosage presentations, which may differ by country.
Label lists a specific U.S. injection presentation but does not discuss Mexico-specific or cross-country presentation differences.
In Mexico, dispensing may require a Mexican prescription format.
No provided label text addresses country-specific prescription/dispensing format requirements.
If Victoza is not stocked, many pharmacies can check whether liraglutide is sold under another brand.
No provided label text addresses pharmacy substitution to other liraglutide brands when Victoza is unavailable.
If Victoza is not stocked, many pharmacies can check whether an alternative GLP-1 option is available.
No provided label text addresses switching/substitution to alternative GLP-1 options due to stock availability.
If Victoza cannot be found or is costly, a pharmacy typically checks for another liraglutide brand.
No provided label text supports cost/availability-driven substitution instructions.
Another liraglutide brand would have the same active ingredient.
Label confirms VICTOZA contains liraglutide but does not address whether other liraglutide brands have the same active ingredient.
If Victoza cannot be found or is costly, a pharmacy typically checks for a different GLP-1 medicine.
No provided label text supports substituting to a different GLP-1 medicine based on inability to find or cost.
A different GLP-1 medicine is in the same class as Victoza but has a different dosing schedule.
No provided label text discusses other GLP-1 medicines, their class relationship, or dosing schedules.
If applicable in Mexico, pharmacies may check for generic or biosimilar options.
No provided label text addresses generics/biosimilars or Mexico-specific pharmacy practices.
The best alternative option depends on what a clinician prescribed and the treatment plan, including dose titration and tolerance for GLP-1 therapies.
The label includes titration/counseling information for VICTOZA but does not support generalized guidance on selecting alternative therapies/GLP-1 tolerability when Victoza is unavailable.
Mexico drug supply can vary due to country-specific approval and labeling.
No provided label text addresses country-specific approval/labeling effects on supply.
Mexico drug supply can vary due to import/distribution contracts.
No provided label text addresses import/distribution contract effects on supply.
Mexico drug supply can vary based on whether the brand is currently in stock at local wholesalers.
No provided label text addresses wholesaler stock variability.
You cannot assume Victoza availability in Mexico based on the U.S. or EU situation.
No provided label text addresses cross-country availability assumptions.
DrugPatentWatch.com can be a useful starting point for background on liraglutide-related intellectual property and brand landscape.
No provided label text references DrugPatentWatch.com or provides guidance about external IP/brand resources.
Contradictions
Important Omissions
No label-supported safety/boxed warning content was provided alongside the Mexico/pharmacy substitution guidance (e.g., counsel on thyroid C-cell tumors, pancreatitis, hypoglycemia, etc., as applicable to VICTOZA use).
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Medium
The response includes operational guidance about verification and substitution of GLP-1 therapies/brands based on availability/cost that is not supported by the provided prescribing information, which could contribute to improper substitution or dosing changes not addressed in the label text supplied.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Not Aligned
Primary Issue
Most claims are not supported by the provided FDA prescribing information, especially Mexico/pharmacy operational steps and substitution/alternative GLP-1 selection guidance.
Suggested Improvement
Limit statements to label-supported indications and, if discussing patient safety or use, reference only label-supported counseling/warnings. Remove or reframe Mexico-specific availability and pharmacy verification/substitution claims that are not present in the provided label text.